Interleukin 17 receptor in multiple sclerosis patients treated with interferon β-1a

Folia Neuropathologica

Volumn 49, Issue 2, 2011, Pages 138-141

  Michałowska Wender, Grazyna ^a,b   Biernacka Łukanty, Justyna ^b   Lasik, Zofia ^b   Jernas, Łukasz ^b   Wender, Mieczysław ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Interferon 1a; Interleukin 17; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 17 RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PHARMACODYNAMICS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RELAPSE; REMISSION;

EID: 79960444201     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011; 23: 1069-1075.
2. Das Sarma J, Ciric B, Marek R, Sadhukhan S, Caruso ML, Shafagh J, Fitzgerald DC, Shindler KS, Rostami A. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflammation 2009; 28: 6-14.
3. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010; 74 Suppl. 1: S17-24.
4. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP. Il17 and IFNγ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 2008; 44: 22-25.
5. Gaffen SL. An overview of Il-17 function and signaling. Cytokine 2008; 43: 402-407.
6. Gaffen SL, Kramer JM, Yu JJ, Shen F. The Il-17 cytokine family. Vitam Horm 2006; 74: 255-282.
7. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-567.
8. Gold R, Lühder F. Interleukin-17 - extended features of a key player in multiple sclerosis. Am J Pathol 2008; 172: 8-10. (Pubitemid 351186362)
9. Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, Kaplin AI, Nath A, Kerr DA, Calabresi PA. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 2008; 196: 124-132.
10. Ivanov S, Lindèn A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009; 30: 95-103.
11. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of Il-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226: 57-79.
12. Jaśkiewicz E, Michałowska-Wender G, Pyszczek A, Wender M. Recombinant forms of myelin antigens expressed on Chinese hamster ovary (CHO) cells as a tool for identification of autoantibodies in serum of multiple sclerosis patients. Folia Neuropathol 2010; 48: 45-48.
13. Jurewicz A, Matysiak M, Tybor K, Selmaj K. TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3. Brain 2003; 126: 1358-1370. (Pubitemid 36644381)
14. Kappos L, Clanet M, Sandberg-Wolheim M. i wsp. Neutralizing antibodies and efficacy of interferon beta 1a: a 4 year controlled study. Neurology 2005; 65: 40-47.
15. Karp CL, Biron CA, Irani DN. Interferon β in multiple sclerosis: is IL-17 suppression the key? Immunol Tuday 2000; 21: 24-28.
16. Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-104. (Pubitemid 29186827)
17. LA Tesmer, SK Lundy, S. Sarkar, DA Fox. Th17 cells in human disease. Immunol Rev 2008; 223: 87-113. (Pubitemid 351986173)
18. Losy J, Michałowska-Wender G. In vivo effect of interferon-β 1a on interleukin-12 and TGF-β1 cytokines in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2002; 106: 44-46.
19. Losy J, Michałowska-Wender G, Wender M. Chemokines MIP-1 and MCP-1 and patients with multiple sclerosis treated with interferon beta-1a. Neurol Neurochir Pol 2001; 35: 583-588.
20. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009; 183: 5418-5427.
21. Ramgolam VS, Markovic-Plese S. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocr Metab Immune Disord Drug Targets 2010; 10: 161-167.
22. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp Cell Res 2011, Mar 21. [Epub ahead of print].
23. Sarah L, Gaffen SL. Structure and signaling in the IL-17 receptor superfamily. Nat Rev Immunol 2009; 9: 556-571.
24. Sarah L, Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008; 43: 402-407.
25. Spriggs M. Interleukin-17 and its receptor. J Clin Immunol 1997; 17: 366-369. (Pubitemid 27431975)
26. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system - infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146-151.
27. Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, Vanden-Bos T, Zappone JD, Painter SL, Armitage RJ. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997; 9: 794-800. (Pubitemid 27494143)
28. Zhang X, Angkasekwinai P, Dong C, Tang H. Structure and function of interleukin-17 family cytokines. Protein Cell 2011; 2: 26-40.
29. Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Su H, Pan FM, Li WX, Li LH, Chen GP, Ye DQ. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37: 81-85.